FORMA Meets Objective with Celgene to Advance a Novel Protein Homeostasis Program

FORMA Therapeutics has successfully completed a critical objective under its strategic collaboration agreement with Celgene, triggering an undisclosed payment from Celgene. Previously, FORMA and Celgene entered into a collaboration in the promising area of protein homeostasis to discover, develop and commercialize innovative drug candidates. This collaboration enables Celgene to evaluate select therapeutic candidates and programs in protein homeostasis during preclinical development.

"We are pleased with Celgene’s continued confidence in FORMA’s discovery research. This program represents a potential first-in-class therapeutic mechanism, by conferring both anti-tumor and immune-modulatory effects," Jim Winkler, Ph.D., Vice President, Biology at FORMA Therapeutics said. "We believe the field of protein homeostasis will deliver a promising pipeline of drugs, moving beyond cancer into immuno-oncology, inflammation and neurodegeneration."

Register as Visitor to CPhI China 2018!